Tag:
generics
Latest Headlines
Latest Headlines
Impax cited by FDA in manufacturing inspection
Fresh off dropping $130 million to license AstraZeneca's Zomig, drug delivery firm Impax Pharmaceuticals faces a citation from the FDA for its manufacturing practices.
Ranbaxy to make drugs in Malaysia, Nigeria
Indian genericsmaker Ranbaxy Laboratories is on a bit of an expansion binge.
Patent cliff could create need for novel delivery tech
As blockbusters go off patent and generics companies scramble to compete, novel drug delivery tech could be the difference-maker in the marketplace.
Genericsmaker banking on novel delivery to raise funds
Arkansas' Ezra Innovations is hoping its proprietary extended-release delivery tech can help it close a $6.5 million funding round.
Ranbaxy shipping generic Lipitor from new Indian plant
Ranbaxy Laboratories has a new FDA-approved plant in India from which it is shipping a generic Lipitor to the U.S.
UPDATED: Supreme Court upholds Unigene's nasal delivery patent
Unigene Laboratories can hold on to its patent for Fortical, after the Supreme Court denied Apotex's petition this week.
Teva's Cephalon recalls leukemia drug over fragments in vial
Teva Pharmaceutical Industries' ( $TEVA ) Cephalon has recalled one lot of leukemia drug Treanda after glass fragments were found in one of the vials. FDA-approved labeling for Treanda states that...
Report: Big Pharma finds Indian collaborations costly
Big Pharma is getting bitten by its deals with Indian generics-makers. One recent example, of course, is Japan's Daiichi Sankyo, which last month felt tremors from Indian unit Ranbaxy as the latter
Generics makers step up for shortages response
The FDA is "not necessarily the best organization to provide notification on shortages," Ralph Neas told Reuters last week, amid a seeming riot of actions and announcements targeting the prevention
UPDATED:Drugmakers respond to shortages order, HHS report
Generic drugmakers have pledged to work with the FDA to formalize the process for manufacturers and other members of the supply chain to report drug shortages to the FDA, "as many now do
